Gemcitabine combined with cisplatin as first-line treatment in patients with epithelial ovarian cancer: A phase II study

Gynecologic Oncology

Volumn 91, Issue 1, 2003, Pages 32-38

  Belpomme, D ^a   Krakowski, I ^b   Beauduin, M ^c   Petit, T ^d   Canon, J L ^e   Janssens, J ^f   Gauthier, S ^a   De Pauw, A ^g   Moreau, V ^h   Kayitalire, L ⁱ  

^a Hopital Boucicaut   (France)

^b Jean Monnet Hospital   (France)

^c Centre Hospitalier Jolimont Lobbes   (Belgium)

^d CENTRE PAUL STRAUSS   (France)

^e Clinique Notre Dame   (Belgium)

^f Salvator Hospital   (Belgium)

^g Eli Lilly Benelux   (Belgium)

^h Eli Lilly France   (France)

ⁱ ELI LILLY AND COMPANY   (United States)

Author keywords

Chemonaive; Cisplatin; Gemcitabine; Ovarian cancer

Indexed keywords

CISPLATIN; GEMCITABINE;

ADULT; AGED; ALOPECIA; ANEMIA; ARTICLE; CANCER GROWTH; CANCER STAGING; CANCER SURVIVAL; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIARRHEA; DOSE CALCULATION; DOSE RESPONSE; DRUG EFFICACY; DRUG SAFETY; DYSPNEA; FEMALE; FOLLOW UP; HUMAN; INFECTION; LEUKOPENIA; LUNG DISEASE; MULTICENTER STUDY; NAUSEA; NEUROTOXICITY; NEUTROPENIA; OTOTOXICITY; OVARY CANCER; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; THROMBOCYTOPENIA; TREATMENT OUTCOME; VOMITING;

EID: 0141757486     PISSN: 00908258     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0090-8258(03)00413-X     Document Type: Article

References (22)

1. Parkin D.M., Pisani P., Ferlay J. Global cancer statistics. CA Cancer J Clin. 49:1999;33-64.
2. Ozols R.F., Young R.C. Chemotherapy of ovarian cancer (review). Semin Oncol. 18:1991;222-232.
3. Chemotherapy in advanced ovarian cancer an overview of randomised clinical trials . BMJ. 303:1991;884-893.
4. Parkin M.D., Pisani P., Ferlay J. Global cancer statistics. CA Cancer J Clin. 49:1999;33-64.
5. Randomised comparison of cisplatin with cyclophosphamide/cisplatin and with cyclophosphamide/doxorubicin/cisplatin in advanced ovarian cancer. Lancet. 2:1987;353-359.
6. Bruckner H.W., Wallach R., Cohen C.J., Deppe G., Kabakow B., Ratner L., Holland J.F. High-dose platinum for the treatment of refractory ovarian cancer. Gynecol Oncol. 12:1981;64-67.
7. Allen D.G., Baak J., Belpomme D., Berek J.S., Bertelsen K., ten Bokkel Huinink W.W., et al. Advanced epithelian ovarian cancer 1993 consensus statements (review) . Ann Oncol. 4:(suppl 4):1993;83-88.
8. McGuire W.P., Hoskins W.J., Brady M.F., Kucera P.R., Partridge E.E., Look K.Y., et al. Cyclophosphamide and cisplatin compared with paclitaxel and cisplatin in patients with stage III and stage IV ovarian cancer. N Engl J Med. 334:1996;1-6.
9. Piccart M.J., Bertelsen K., James K., Cassidy J., Mangioni C., Simonsen E., et al. Randomized intergroup trial of cisplatin-paclitaxel versus cisplatin-cyclophosphamide in women with advanced epithelial ovarian cancer three-year results . J Natl Cancer Inst. 92:2000;699-708.
10. Harper P. A randomised comparison of paclitaxel (T) and carboplatin (J) versus a control arm of single agent carboplatin (J) or CAP (cyclophosphamide, doxorubicin and cisplatin) 2075 patients randomised into the 3rd International Collaborative Ovarian Neoplasm Study (ICON3) . Proc Am Soc Clin Oncol. 18:1999;356a. (No. 1375).
11. Muggia F.M., Braly P.S., Brady M.F., Sutton G., Niemann T.H., Lentz S.L., et al. Phase III randomized study of cisplatin versus paclitaxel versus cisplatin and paclitaxel in patients with suboptimal stage III or IV ovarian cancer a Gynecologic Oncology Group study . J Clin Oncol. 18:2000;106-115.
12. Lund B., Hansen O.P., Theilade K., Hansen M., Neijt J.P. Phase II study of gemcitabine (2′,2′-difluorodeoxycytidine) in previously treated ovarian cancer patients. J Natl Cancer Inst. 86:1994;1530-1533.
13. von Minckwitz G., Bauknecht T., Visseren-Grul C.M., Neijt J.P. Phase II study of gemcitabine in ovarian cancer. Ann Oncol. 10:1999;853-855.
14. Friedlander M., Millward M.J., Bell D., Bugat R., Harnett P., Moreno J.A., et al. A phase II study of gemcitabine in platinum pre-treated patients with advanced epithelial ovarian cancer. Ann Oncol. 9:1998;1343-1345.
15. Shapiro J.D., Millward M.J., Rischin D., Michael M., Walcher V., Francis P.A., Toner G.C. Activity of gemcitabine in patients with advanced ovarian cancer responses seen following platinum and paclitaxel . Gynecol Oncol. 63:1996;89-93.
16. McGuire W.P., Ozols R.F. Chemotherapy of advanced ovarian cancer (review). Semin Oncol. 25:1998;340-348.
17. Peters G.J., Bergman A.M., Ruiz van Haperen V.W., Veerman G., Kuiper C.M., Braakhuis B.J. Interaction between cisplatin and gemcitabine in vitro and in vivo. Semin Oncol. 22:(4 suppl 11):1995;72-79.
18. Sandler A.B., Nemunaitis J., Denham C., von Pawel J., Cormier Y., Gatzemeier U., et al. Phase III trial of gemcitabine plus cisplatin versus cisplatin alone in patients with locally advanced or metastatic non-small-cell lung cancer. J Clin Oncol. 18:2000;122-130.
19. von der Maase H., Hansen S.W., Roberts J.T., Dogliotti L., Oliver T., Moore M.J., et al. Gemcitabine and cisplatin versus methotrexate, vinblastine, doxorubicin, and cisplatin in advanced or metastatic bladder cancer results of a large, randomized, multinational, multicenter, phase III study . J Clin Oncol. 18:2000;3068-3077.
20. Nogue M., Cirera L., Arcusa A., Batiste-Alentorn E., Balil A., Font A., et al. Phase II study of gemcitabine and cisplatin in chemonaive patients with advanced epithelial ovarian cancer. Anticancer Drugs. 13:2002;839-845.
21. Bauknecht T, Hefti A, Morack G, Villena-Heinsen C, Wallwiener D, Elling D. Gemcitabine combined with cisplatin as first-line treatment in patients 60 years or older with epithelial ovarian cancer: a phase II study. Int J Gynecologic Cancer 2003;13:130-7.
22. Hansen S.W., Anderson H., Boman K., Hansen M., Havsteen H., Rosenberg P., et al. Gemcitabine, carboplatin, and paclitaxel (GCP) as first-line treatment of ovarian cancer FIGO stages IIB-IV. Proc Am Soc Clin Oncol. 18:1999;357a. (No. 1379).